Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 29, 2018
Prometic Announces Extension of Debt Maturities to 2024
LAVAL, QC , Oct. 29, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") announced today that it has signed a binding letter ...
October 29, 2018
miRagen Therapeutics to Present at two Investor Conferences in November 2018
BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
October 29, 2018
Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials
BUFFALO, N.Y., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
October 29, 2018
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
LEIDEN, the Netherlands, Oct. 29, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR) a company dedicated to changing lives through the creation of transformative RNA ...
October 29, 2018
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
October 29, 2018
BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa ...
October 29, 2018
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug ...
October 29, 2018
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the third quarter and ...
October 29, 2018
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver ...
October 29, 2018
Acer Therapeutics Submits NDA for EDSIVO™ for the Treatment of vEDS
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
October 29, 2018
BioDelivery Sciences Announces Changes to its Executive Leadership Team
RALEIGH, N.C., Oct. 29, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic ...
October 29, 2018
Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018
HOPKINTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
October 24, 2018
Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis
Pratteln, Switzerland, October 24, 2018 - Santhera Pharmaceuticals (SANN.SW) announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with ...
October 24, 2018
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
October 24, 2018
Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology ...
October 24, 2018
RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
October 24, 2018
Genkyotex Provides Corporate Update and Reports Cash Position at September 30, 2018
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provides a business update, including ...
October 23, 2018
iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results
NASHUA, N.H. and SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- (Booth #3457) – iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection ...
October 23, 2018
HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
TUCSON, Ariz., Oct. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, ...
October 23, 2018
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
PITTSBURGH, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for ...
Page 19 of 127